Today’s cell and gene therapies are proving themselves to be viable
entities. However, as more products leave the clinic for commercialization, new questions emerge: Is enough manufacturing capacity available? How do companies
reduce cost of goods (CoG) and increase manufacturing efficiency? Should a developer build its own capabilities or use a third party? What benefits can a contract development and manufacturing organization (CDMO) bring to this space?

BioProcess Insider editor Dan Stanton posed these questions to a range of industry leaders during a rountable discussion at the Wednesday, 5 June 2019, session of the BPI Theater at BIO. Panelists included Joseph Rininger, director of cell and gene therapy at the Latham Biopharm Group; Felix Hsu, senior vice president and global head at WuXi Advanced Therapies; Soenke Brunswieck, vice president of cell and gene therapies at the Celonic Group; and Joe Vitale, director and account management at Hitachi Chemical.

Watch the full roundtable discussion below and leave your thoughts or questions on the topic below in the comments.